Major comments: Treg cells play critical roles in immune tolerance. However, the contribution of chromatin structure and modification to the function of Treg cells is not well understood. This study addresses the function of ATP-dependent chromatin remodeling, which is one of the two major chromatin modification processes. The authors find that BRG1 regulates the early stages of Treg activation. Another interesting finding is that chromatin remodeling-independent activities of BRG1 is critically involved in Treg function. Although it is not clear yet what are the specific nonchromatin-remodeling activities that contribute to Treg function, the discussion provides some interesting ideas. The study is well designed and most of the results are clean and convincing. Overall, this is an interesting study that provides valuable new information and I think it is suitable for publication.
Referee #2
In this study the investigators have reported a role of BRG1 in regulating Treg function. Deletion of BRG1 either in CD4+ or regulatory T cells leads to fatal autoimmune diseases in mice. Although Treg development or in vitro suppressive function is not affected by BRG1 deletion in CD4+ T cells, BRG1 deficiency impaired Treg activation in a variety of ways. First, the induction of a variety of functional important genes was decreased. This included chemokine receptor genes CCR2, CXCR3 that are involved in Treg trafficking, Cd103 that are required for Treg retention, and Icos that are important for the suppressive activity of Treg cells. Secondly, Treg proliferation wasly impaired in vivo. Third, several TCR target genes are not properly up-regulated upon stimulation. Taken together, these defects contribute to the onset of inflammation. Additionally, the defects of mice carrying an ATPase point mutation in BRG1 was weaker when compared to mice with BRG1 deletion.
This study revealed a possible role of BRG1 in immune tolerance, which is partly remodeling independent. While the data in this study are clearly presented each defect of BRG1 deficient Tregs reported is modest not convincing and the specific mechanism responsible for the fatal inflammation caused by BRG1 deletion in Tregs remains to be identified. The data is not convincing and is better suited for a specialty journal.
Specific comments:
1. In Figure 7 , it is stated that 21% (79% after injection -58% before injection) of Treg cells upregulate CXCR3 following ConA injection. However, it is also stated later that CXCR3+ Tregs are recruited to the liver after ConA injection, so it is not likely that one is able to calculate the percentage of CXCR3 upregulated Tregs in this way. It is hard to discern how many cells upregulated CXCR3 in the liver and how many cells are recruited to the liver. To investigate the percentage of CXCR3 up-regulated Tregs, the investigator should perform in vitro studies to check the expression level of Treg activation markers in response to stimulation.
2. The in vitro suppressive function of Tregs is not affected by BRG1 deletion in CD4+ T cells compared to normal Treg cells. This is unexpected since the expression of some functionally important genes such as Icos is impaired in BRG1 deficient Treg cells. Considering the fact that the difference of some Treg activation marker's expression can only be detected under noninflammation conditions, or during ConA-induced inflammation, it would be useful to compare the suppressive function of YFP-and YFP+ Tregs from Brg1F/F, Foxp3 YFP-Cre/+ female mice, or to compare the suppressive function of YFP+ Treg from Brg1F/F, Foxp3 YFP-Cre/+ female mice and YFP+Treg from Brg1F/+, Brg1F/+, Foxp3 YFP-Cre/+ female mice during ConA-induced inflammation.
3. In Figure 1G , the labeling and the figure should be aligned.
Referee #3
Review of EMBO J manuscript EMBOJ-2012-83703, "Essential roles of BRG1 in immune tolerance: Priming of Treg activation and partial independence of chromatin remodeling," submitted by Chi, Flavell, and co-workers This interesting and important manuscript has two general items as its primary areas of exploration. The first constitutes work towards a deeper understanding of molecular programming in T lymphocytes, here focusing on balancing the conventional effector capabilities of CD4 T cells against the number or function of suppressive Treg cells. The second area of investigation and impact is that of elucidating the extent to which particular biological functions of the BRG1 protein depend on its ATPase function vs ATPase-independent functions of BRG1.
The principal findings reported in the data set and manuscript text get at two main findings that this reader felt are very highly significant. First, BRG1 is vital for a Treg-intrinsic function that is crucial (within the mouse as a whole) in suppressing activation and inflammatory tendencies of conventional T cells but operates at a relatively novel checkpoint. The number and in vitro suppressive competence of the BRG1-deficient Treg cells were not at fault, rather something about function in vivo. While not completely sealing the deal as to what that "something" might be, the data of the manuscript offer substantial support to the model that there is a coordinated BRG1-dependent program of chemokine receptor gene regulation. To this reader's view, the data presented are sufficient as a 'first paper case' for this chemokine receptor & trafficking model as a way to integrate the findings. Overall, this part of the work is of meritorious and of high priority.
The second point is that by sophisticated use of a knock-in allele, the workers generated evidence that the general or overall role of BRG1 mixes ATPase dependent functions of BRG1 with ATPaseindependent roles in the Treg function. This latter point is not extensively developed -which for the most part is reasonable given how extensive are the figures and data for the first finding -but does hinge almost exclusively on a difference between the Kaplan-Meier curve (survival across time) between the hemizygous point mutant mice and both WT controls and the straight null mice ( Figure  9A ). This latter finding, if sufficiently solid, is of high value because although most everyone in the field accepts that BRG1 can have ATPase-independent functions -and even function outside of the conventional BAF (Swi-SNF) complex that this investigator has helped pioneer and championthose studies are conducted in transfected cells or in setting that otherwise have shortcomings in terms of modeling physiological concentrations, regulation, and the biology of an overall animal or system.
Although this body of work is strong and merits a high priority, a few points pertained that should be dealt with or improved.
More major: 1. Figure 8B presents ChIP results from a single experiment. Although the norm of the field has moved to merges of multiple biological replicates, the presentation here would be OK if a repeat were presented. The text states that such data are in supplemental figure S3B and the version of manuscript and figures available to this reader lacks a panel B.
2. The interpretation of the findings of Figure 9 -especially panel A -and the point-mutated BRG1 allele ("Brg1 0") depends on a comparison to both "WT" and complete loss-of-expression ("Brg1 F/F"). This interpretation depends on equivalence of the deletion efficiency of the F allele in the F/O mice to that in the F/F mice, and furthermore depends on the absence of an effect of having hemizygosity for functional ATPase-active BRG1. Therefore: a. While noting and appreciating the challenges and the helpfulness of reporter alleles, it would be helpful to have PCR evidence from flow-sorted FoxP3+ cells of the F/F and F/0 mice to provide the reader a picture of the completeness of deletion in each setting. It is unlikely that the F allele would delete less well in the F/0 setting, but if it did, that could allow the mice to live longer, as observed in 9B. A reporter allele might in principle be helpful, but it has to be noted that they do not necessarily track perfectly with excision.
b. Conversely, how to control for the survival curve of "WT" is not simple and at a minimum the text has to note this complexity. With complete deletion, the level of BRG1 expression in a F/0 mouse or cell is really most equivalent to F/+ (F/wt), so that in fact the FoxP3-Cre, F/wt mouse would be the most appropriate control. Again, it would be less satisfying as a control, but since the steady-state protein expression of BRG1 is influenced substantially by its need to be incorporated into complexes (that is, extra protein gets degraded), flow cytometric analysis of the level of BRG1 protein in the Treg-like cells of "WT", "F/0", and "F/F" mice akin to those used in the experiments of More minor:
At some points, attention to and improvement in the writing style and quality are warranted. A particularly apt example is "such a lame reaction would be "too late and too weak" (late on p. 17). The frequent practice of splitting out conclusion sentences, separate from the paragraph, might be thought helpful during review stages of a text, but really is not. More generally, for the field, referring to the ATPase-independent function as "unconventional" is unhelpful -there is enough evidence that this is part of how BRG1 works, and indeed that it works outside of BAF complexes, that the concept that it is a convention is neither valid nor helpful. We show that Brg1 KO in Tregs caused fatal inflammation, which is associated with the defects in the induction of a number of functionally important TCR target genes including those encoding vital trafficking molecules. It is true that the defect in the expression of each gene is modest, but very likely, the multiple defects may conspire to cause or at least contribute to the fatal inflammation, as we stated in the ms, which the other two reviewers fully agreed. It is true that we have yet to conclusively prove the causation between the activation defect and the fatal inflammation, which is a limitation of the paper. However, to prove the causation, one would need to show that forced expression of various misregulated TCR target genes can in combination rescue the phenotype, which is not trivial and we believe is beyond the scope of the current paper. This is because despite the above-mentioned limitation, our study has conclusively established BRG1 as the first chromatin remodeling factor essential for Treg function and the first transcription factor facilitating Treg activation, and suggested (albeit not proven) a strong plausible link between the two. Furthermore, our study demonstrates for the first time the biological importance of ATPase-independent activity of any chromatin remodeling factor in mice. In our view, the story is interesting to the readers of the Embo Journal, as the other two reviewers pointed out. Regarding the suggested in vitro experiment, we apologize for any confusion. The goal of the Con A experiment is to determine whether Brg1 KO impairs Treg activation and trafficking in response to "pathological inflammatory signals" in vivo. The nature of the Con A-induced pathological inflammatory signals in vivo is, to our knowledge, unclear, but presumably a combination of TCR ligation and inflammatory cytokines is involved. While the TCR ligation may be reproducible in vitro, the cytokine milieu is not. Furthermore, the in vitro assay cannot assess trafficking. We thus believe the Con A experiment should be done in vivo for our purpose.
This said, we did appreciate the point that in vitro assays can eliminate any potential confounding effects of trafficking when calculating the induction efficiency. Furthermore, it allows the effect of TCR ligation to be dissociated with that of proinflammatory cytokines. We have actually examined Treg activation in vitro in response to TCR stimulation (by anti-CD3/CD28 beads). The in vitro assay partially (but not completely) recapitulates the activation defects in vivo ( Fig. 8 ; see also the response to reviewer's second point below). Of note, in these assays, we used qRT-PCR rather than FACS to quantify induction of TCR target genes, in part because FACS proves unreliable due to high autofluorescence after in vitro culture. It is indeed disappointing that Brg1 KO did not affect Treg function in vitro. However, the in vitro assay only measures the effect of Tregs on the proliferation of CD4 T cells, whereas Tregs have many other functions in vivo essential for immune suppression. Thus, the autoimmunity in Brg1 KO mice might reflect the role of BRG1 in these other functions and cannot be detected by the in vitro assay. Indeed, we have found BRG1 KO impairs the induction of a number of TCR target genes, including multiple trafficking molecules (Fig. 8) . These genes are presumably functionally important in vivo, but none of them seem important for Treg suppression in vitro. Of note, while Brg1 KO impairs Icos induction in vivo, and Icos may be important for Treg suppression vitro as the reviewer pointed out, Icos induction is normal in vitro (Fig. 8) , perhaps because of anti-CD3/CD28 mediated TCR stimulation is strong enough to bypass the need of BRG1in Icos induction. Thus, the in vitro suppression assay cannot recapitulate many aspects of Treg function, nor can it faithfully reproduce the activation defects in Brg1 KO Tregs observed in vivo. We therefore feel that this assay is not ideal for revealing BRG1 function, and that it is beyond the scope of this paper to do the suggested experiments, although we would keep it a long-term goal trying to detect a role of BRG1 in Treg-suppression in vitro, which would facilitate mechanistic studies.
2) The in vitro suppressive function of Tregs is not affected by BRG1 deletion in CD4+ T cells compared to normal Treg cells. This is unexpected since the expression of some functionally important genes such as Icos is impaired in BRG1 deficient Treg cells. Considering the fact that the difference of some Treg activation marker's expression can only be detected under noninflammation conditions, or during
3). In Figure 1G , the labeling and the figure should be aligned.
We apologize for the oversight; this error has been corrected.
Referee #3

This interesting and important manuscript has two general items as its primary areas of exploration. The first constitutes work towards a deeper understanding of molecular programming in T lymphocytes, here focusing on balancing the conventional effector capabilities of CD4 T cells against the number or function of suppressive Treg cells. The second area of investigation and impact is that of elucidating the extent to which particular biological functions of the BRG1 protein depend on its ATPase function vs ATPase-independent functions of BRG1.
The principal findings reported in the data set and manuscript text get at two main findings that this reader felt are very highly significant. First, BRG1 is vital for a Treg-intrinsic function that is crucial (within the mouse as a whole) in suppressing activation and inflammatory tendencies of conventional T cells but operates at a relatively novel checkpoint. The number and in vitro suppressive competence of the BRG1-deficient Treg cells were not at fault, rather something about function in vivo. While not completely sealing the deal as to what that "something" might be, the data of the manuscript offer substantial support to the model that there is a coordinated BRG1-dependent program of chemokine receptor gene regulation. To this reader's view, the data presented are sufficient as a 'first paper case' for this chemokine receptor & trafficking model as a way to integrate the findings. Overall, this part of the work is of meritorious and of high priority.
The second point is that by sophisticated use of a knock-in allele, the workers generated evidence that the general or overall role of BRG1 We are very grateful that the reviewer has carefully read the paper and is highly positive about the study. We apologize for the oversight. We have now added Fig. S3B . Figure 9 -especially panel A -and the point-mutated BRG1 allele ("Brg1 0") depends on a comparison to both " (Fig. 9G) . As the primer pair that detects Brg F also amplifies Brg O (and its converted form Brg*), qPCR was not applicable and the quantitation was instead based on end-point duplex PCR, with Brg O (and Brg*) serving as the internal control, as previously described (Jani et al., 2008) . As the reviewer predicted, and as our previous data indicated, Brg1 F was deleted effectively in the F/O setting, with the amplicon present in the tail DNA but undetectable in Tregs (Fig. 9G, lanes 1 vs. 3 Indeed, the most appropriate control for the point mutant mice would be mice lacking one copy of Brg in Tregs, so that the abundance of WT vs. point mutant BRG would be (nearly) identical. For practical reasons, we have used both the het mice and the mice carrying both alleles of Brg as "WT" controls for the point mutant mice. We felt this is acceptable because the potential error introduced by the latter mice would be exaggeration of the defect in the point mutant, which is an error on the conservative side. In other words, if the het mice were used exclusively, then the phenotype of the point mutation might appear even weaker, further highlighting the role of non-catalytic function of the BAF complex, a key conclusion of the paper. Of course, as the reviewer pointed out, ultimately, we need to directly quantify the protein abundance to make any solid conclusion, but unfortunately, we have been unable to use FACS to detect BRG, and Western blot is not quantitative enough for such an application.
The interpretation of the findings of
We have modified the text as follows: 1) in Fig. 2 legend, we stated that the "Brg1-sufficient mice carried one or two functional Brg1 alleles". 2) Under discussion (p19), we inserted: "Of note, the role of RIF may have been underestimated in the current study, because the defects in the PM mice were compared to "WT" control mice some of which carried two functional Brg alleles in Tregs (see Fig. 2 legend) . Thus, BRG1 abundance in the control mice was perhaps higher than the ATPase-dead mutant, as the latter is expressed from a single copy (Jani et al., 2008) , which might have exaggerated the defects in the PM mice, leading to the overestimation of the importance of the ATPase activity". We apologize for our miscommunication. The "O" allele is null by default, but converted into the kinase-dead protein only after Cre expression (Jani et al., 2008 
